Eli Lilly beats and raises as GLP-1 demand drives quarterly results
Shares rose after the company lifted guidance on the back of incretin franchise sales.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: Schaeffer's Investment Research
The wire
- 01Eli Lilly reported quarterly results above expectations and raised guidance, with GLP-1 demand cited as the main driver; the stock rose on the report.
- 02Lilly's tirzepatide franchise performance shapes supply, pricing and the competitive picture against Novo Nordisk for clinicians and telehealth operators.
- 03Specific revenue and guidance figures were not detailed in the report summary; the raise reflects company projections rather than realized sales.
From the source
Read at schaeffersresearch.comEli Lilly Stock Rises as GLP-1 Demand Drives Beat-and-Raise
